De mest almindelige bivirkninger, der førte til afbrydelse af forsøget for BYETTA- behandlede patienter, var kvalme (4% af patienterne) og opkastning (1%).
The most common adverse events leading to withdrawal for BYETTA-treated patients were nausea (4% of patients) and vomiting (1%).